{"id":64696,"date":"2026-05-08T14:06:34","date_gmt":"2026-05-08T06:06:34","guid":{"rendered":"https:\/\/flcube.com\/?p=64696"},"modified":"2026-05-08T14:06:35","modified_gmt":"2026-05-08T06:06:35","slug":"chinas-seven-ministries-issue-revised-pharmaceutical-representative-management-measures-to-combat-commercial-bribery-and-strengthen-industry-oversight","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=64696","title":{"rendered":"China&#8217;s Seven Ministries Issue Revised Pharmaceutical Representative Management Measures to Combat Commercial Bribery and Strengthen Industry Oversight"},"content":{"rendered":"\n<p>China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong>, in coordination with six other regulatory bodies, has jointly issued comprehensive <strong>&#8220;Measures for the Management of Pharmaceutical Representatives,&#8221;<\/strong> replacing the 2020 interim regulations with a robust framework designed to <strong>eliminate commercial bribery<\/strong>, enhance transparency, and establish clear accountability across the pharmaceutical promotion ecosystem.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-framework-overview\">Regulatory Framework Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Key Features<\/th><\/tr><\/thead><tbody><tr><td><strong>Scope<\/strong><\/td><td>Six chapters, 35 articles covering MAH responsibilities, representative qualifications, academic promotion standards<\/td><\/tr><tr><td><strong>Oversight Bodies<\/strong><\/td><td>NMPA, Ministry of Public Security, NHC, SAMR, NHSA, National Administration of Traditional Chinese Medicine, National Disease Control and Prevention Administration<\/td><\/tr><tr><td><strong>Implementation Date<\/strong><\/td><td>August 1, 2026 (new representatives); existing records remain valid under &#8220;old rules for old cases&#8221; principle<\/td><\/tr><tr><td><strong>Public Access<\/strong><\/td><td>Pharmaceutical Representative Recordation Platform (https:\/\/pharmareps.cpa.org.cn) enables verification via recordation number or MAH\/representative name<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-core-regulatory-pillars\">Core Regulatory Pillars<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-1-professional-standards-for-pharmaceutical-representatives\">1. Professional Standards for Pharmaceutical Representatives<\/h3>\n\n\n\n<p>The measures establish <strong>clear qualification requirements<\/strong> and behavioral boundaries for pharmaceutical representatives, who are defined as professionals conducting <strong>drug academic promotion<\/strong> on behalf of Marketing Authorization Holders (MAHs).<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Admission Requirements<\/strong>: Associates degree or higher in medicine, pharmacy, or related field, plus relevant theoretical clinical drug knowledge<\/li>\n\n\n\n<li><strong>Recordation Protocol<\/strong>: Mandatory specification of promotion region and upload of compliance commitment letter<\/li>\n\n\n\n<li><strong>Academic Promotion<\/strong>: Nine explicitly prohibited behaviors to prevent commercial bribery and unethical practices<\/li>\n\n\n\n<li><strong>Employment Restrictions<\/strong>: MAHs forbidden from hiring representatives with commercial bribery history; contractual liability required for violations<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-2-enhanced-mah-accountability\">2. Enhanced MAH Accountability<\/h3>\n\n\n\n<p>Marketing Authorization Holders bear <strong>primary responsibility<\/strong> for their representatives&#8217; conduct throughout the entire lifecycle, regardless of whether academic promotion is conducted directly or outsourced to professional organizations.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Full-Chain Management<\/strong>: MAHs responsible for hiring, authorization, recordation, training, and ongoing supervision<\/li>\n\n\n\n<li><strong>Outsourcing Liability<\/strong>: Even when using third-party organizations, MAHs retain ultimate accountability for representative behavior<\/li>\n\n\n\n<li><strong>Prohibited Acts<\/strong>: 22 specific violations outlined for MAHs, including incentivizing prescription volume or providing improper benefits<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-3-institutional-reception-management\">3. Institutional Reception Management<\/h3>\n\n\n\n<p>Medical and health institutions must establish <strong>comprehensive systems<\/strong> to regulate pharmaceutical representative activities within their facilities.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Internal Controls<\/strong>: Institutions responsible for managing both staff conduct and representative interactions<\/li>\n\n\n\n<li><strong>System Requirements<\/strong>: Formal policies governing when, where, and how academic promotion activities may occur<\/li>\n\n\n\n<li><strong>Staff Accountability<\/strong>: Healthcare professionals prohibited from accepting improper benefits or facilitating inappropriate representative access<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-4-multi-agency-enforcement-coordination\">4. Multi-Agency Enforcement Coordination<\/h3>\n\n\n\n<p>The measures eliminate regulatory blind spots through <strong>enhanced inter-agency collaboration<\/strong> and information sharing mechanisms.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Coordinated Oversight<\/strong>: Clear delineation of responsibilities among seven regulatory bodies<\/li>\n\n\n\n<li><strong>Information Sharing<\/strong>: Mandatory lead transfer, case notification, and administrative-criminal justice coordination<\/li>\n\n\n\n<li><strong>Public Disclosure<\/strong>: Administrative penalties publicly disclosed to enable social oversight and market discipline<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-enforcement-and-disciplinary-measures\">Enforcement and Disciplinary Measures<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-joint-disciplinary-actions\">Joint Disciplinary Actions<\/h3>\n\n\n\n<p>Multiple authorities will implement <strong>coordinated sanctions<\/strong> for violations, including:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Public disclosure of violations through official channels<\/li>\n\n\n\n<li>Increased inspection frequency for non-compliant entities<\/li>\n\n\n\n<li>Restrictions on participation in drug procurement activities<\/li>\n\n\n\n<li>Limitations on signing designated medical insurance service agreements<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-risk-control-mechanisms\">Risk Control Mechanisms<\/h3>\n\n\n\n<p>Regulatory bodies may implement <strong>targeted risk mitigation<\/strong> measures within their jurisdiction:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Time restrictions on academic promotion activities in healthcare facilities<\/li>\n\n\n\n<li>Risk warnings issued through the procurement credit evaluation system<\/li>\n\n\n\n<li>Violation records entered into the National Enterprise Credit Information Publicity System<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-assessment\">Market Impact Assessment<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Pharmaceutical Companies<\/strong>: Enhanced compliance costs but reduced corruption risks; need for robust internal monitoring systems<\/li>\n\n\n\n<li><strong>Healthcare Institutions<\/strong>: Streamlined representative management but increased administrative burden for compliance verification<\/li>\n\n\n\n<li><strong>Industry Professionals<\/strong>: Clearer career standards but stricter qualification and behavioral requirements<\/li>\n\n\n\n<li><strong>Patients and Public<\/strong>: Improved trust in prescribing practices and reduced influence of commercial interests on treatment decisions<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding China&#8217;s pharmaceutical representative regulatory implementation. Actual outcomes may vary based on enforcement consistency, industry adaptation, and inter-agency coordination effectiveness.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div class=\"wp-block-file\"><a id=\"wp-block-file--media-3c32154c-fc6e-4f2b-8a5b-10ed9ab48f8d\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1778148233360011009.doc\">1778148233360011009<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1778148233360011009.doc\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-3c32154c-fc6e-4f2b-8a5b-10ed9ab48f8d\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>China&#8217;s National Medical Products Administration (NMPA), in coordination with six other regulatory bodies, has jointly&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[61,4],"tags":[60,67,14,98],"class_list":["post-64696","post","type-post","status-publish","format-standard","hentry","category-legal-ip","category-policy-regulatory","tag-nhc-nhfpc","tag-nhsa-prev-smia","tag-nmpa","tag-samr"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>China&#039;s Seven Ministries Issue Revised Pharmaceutical Representative Management Measures to Combat Commercial Bribery and Strengthen Industry Oversight - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China&#039;s National Medical Products Administration (NMPA), in coordination with six other regulatory bodies, has jointly issued comprehensive &quot;Measures for the Management of Pharmaceutical Representatives,&quot; replacing the 2020 interim regulations with a robust framework designed to eliminate commercial bribery, enhance transparency, and establish clear accountability across the pharmaceutical promotion ecosystem.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=64696\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"China&#039;s Seven Ministries Issue Revised Pharmaceutical Representative Management Measures to Combat Commercial Bribery and Strengthen Industry Oversight\" \/>\n<meta property=\"og:description\" content=\"China&#039;s National Medical Products Administration (NMPA), in coordination with six other regulatory bodies, has jointly issued comprehensive &quot;Measures for the Management of Pharmaceutical Representatives,&quot; replacing the 2020 interim regulations with a robust framework designed to eliminate commercial bribery, enhance transparency, and establish clear accountability across the pharmaceutical promotion ecosystem.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=64696\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-08T06:06:34+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-08T06:06:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64696#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64696\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"China&#8217;s Seven Ministries Issue Revised Pharmaceutical Representative Management Measures to Combat Commercial Bribery and Strengthen Industry Oversight\",\"datePublished\":\"2026-05-08T06:06:34+00:00\",\"dateModified\":\"2026-05-08T06:06:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64696\"},\"wordCount\":598,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"NHC (NHFPC)\",\"NHSA (prev. SMIA)\",\"NMPA\",\"SAMR\"],\"articleSection\":[\"Legal \\\/ IP\",\"Policy \\\/ Regulatory\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=64696#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64696\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=64696\",\"name\":\"China's Seven Ministries Issue Revised Pharmaceutical Representative Management Measures to Combat Commercial Bribery and Strengthen Industry Oversight - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-05-08T06:06:34+00:00\",\"dateModified\":\"2026-05-08T06:06:35+00:00\",\"description\":\"China's National Medical Products Administration (NMPA), in coordination with six other regulatory bodies, has jointly issued comprehensive \\\"Measures for the Management of Pharmaceutical Representatives,\\\" replacing the 2020 interim regulations with a robust framework designed to eliminate commercial bribery, enhance transparency, and establish clear accountability across the pharmaceutical promotion ecosystem.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64696#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=64696\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64696#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"China&#8217;s Seven Ministries Issue Revised Pharmaceutical Representative Management Measures to Combat Commercial Bribery and Strengthen Industry Oversight\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"China's Seven Ministries Issue Revised Pharmaceutical Representative Management Measures to Combat Commercial Bribery and Strengthen Industry Oversight - Insight, China&#039;s Pharmaceutical Industry","description":"China's National Medical Products Administration (NMPA), in coordination with six other regulatory bodies, has jointly issued comprehensive \"Measures for the Management of Pharmaceutical Representatives,\" replacing the 2020 interim regulations with a robust framework designed to eliminate commercial bribery, enhance transparency, and establish clear accountability across the pharmaceutical promotion ecosystem.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=64696","og_locale":"en_US","og_type":"article","og_title":"China's Seven Ministries Issue Revised Pharmaceutical Representative Management Measures to Combat Commercial Bribery and Strengthen Industry Oversight","og_description":"China's National Medical Products Administration (NMPA), in coordination with six other regulatory bodies, has jointly issued comprehensive \"Measures for the Management of Pharmaceutical Representatives,\" replacing the 2020 interim regulations with a robust framework designed to eliminate commercial bribery, enhance transparency, and establish clear accountability across the pharmaceutical promotion ecosystem.","og_url":"https:\/\/flcube.com\/?p=64696","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-08T06:06:34+00:00","article_modified_time":"2026-05-08T06:06:35+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=64696#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=64696"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"China&#8217;s Seven Ministries Issue Revised Pharmaceutical Representative Management Measures to Combat Commercial Bribery and Strengthen Industry Oversight","datePublished":"2026-05-08T06:06:34+00:00","dateModified":"2026-05-08T06:06:35+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=64696"},"wordCount":598,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["NHC (NHFPC)","NHSA (prev. SMIA)","NMPA","SAMR"],"articleSection":["Legal \/ IP","Policy \/ Regulatory"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=64696#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=64696","url":"https:\/\/flcube.com\/?p=64696","name":"China's Seven Ministries Issue Revised Pharmaceutical Representative Management Measures to Combat Commercial Bribery and Strengthen Industry Oversight - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-05-08T06:06:34+00:00","dateModified":"2026-05-08T06:06:35+00:00","description":"China's National Medical Products Administration (NMPA), in coordination with six other regulatory bodies, has jointly issued comprehensive \"Measures for the Management of Pharmaceutical Representatives,\" replacing the 2020 interim regulations with a robust framework designed to eliminate commercial bribery, enhance transparency, and establish clear accountability across the pharmaceutical promotion ecosystem.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=64696#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=64696"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=64696#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"China&#8217;s Seven Ministries Issue Revised Pharmaceutical Representative Management Measures to Combat Commercial Bribery and Strengthen Industry Oversight"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64696","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=64696"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64696\/revisions"}],"predecessor-version":[{"id":64698,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64696\/revisions\/64698"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=64696"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=64696"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=64696"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}